在患有高血压的成年人中对APOL1的基因检测:GUARDD-US随机临床试验
Michael T Eadon1,2, Kerri L Cavanaugh3, Lilin She4
1Division of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis.
JAMA network open
|March 5, 2026
概括
提供阿波利波蛋白L1 (APOL1) 高风险基因型结果并没有降低整体缩血压 (SBP). 然而,它显著降低了患有失控高血压和慢性病 (CKD) 查和诊断增加的患者的SBP.
科学领域:
- 遗传学和基因组学 遗传学和基因组学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
背景情况:
- 阿波脂蛋白L1 (APOL1) 高风险等位基因与非洲血统个体的慢性病 (CKD) 有关.
- 返回遗传结果,特别是APOL1风险等位基因对血压 (BP) 管理和CKD结果的影响仍未得到充分研究.
研究的目的:
- 评估是否向高血压患者及其临床医生披露APOL1高风险基因型结果,改善了静缩血压 (SBP) 控制.
- 评估APOL1遗传结果对CKD查和诊断率的影响.
主要方法:
- 一项随机对照试验,涉及患有高血压的成年人和自我报告的非洲血统在美国54个临床场所.
- 参与者被分配到立即 (干预) 或6个月后 (控制) 接受APOL1基因型结果,并为CKD查和BP管理提供临床决策支持.
主要成果:
- 在3个月后,干预组和对照组之间没有观察到SBP减少的显著差异.
- 在小组分析中,干预组中患有无控制血压的参与者与对照组相比显示出显著的SBP减少.
- 提供APOL1基因型结果导致尿液微专蛋白查显著增加,6个月后新的CKD诊断.
结论:
- 披露APOL1高风险基因型结果并没有普遍减少SBP,但在没有控制的高血压患者中显示出益处.
- APOL1基因披露显著提高了CKD查和诊断率.
- 进一步调查报告APOL1基因型的影响是有必要的,特别是在不受控制的血压的人群中.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
55
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Human Genetics
1.8K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Hypertension III: Clinical Manifestations and Diagnostic Studies
688
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
688


